Author

L. A. Garraway

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Assay:proteomics· 1 Research Focus:variant calling· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. G. Waks· 1 shared B. Rabasha· 1 shared C. P. Yu· 1 shared D. A. Porter· 1 shared D. Forestier· 1 shared D. Kim· 1 shared D. R. Mani· 1 shared E. Kuhn· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. G. Waks

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Highly multiplexed quantitative phosphosite assay for biology and preclinical studies

H. Keshishian, E. R. McDonald, R. Melanson, D. A. Porter, F. Mundth, K. Krug, L. Wallace, D. Forestier, B. Rabasha, S. E. Marlow, J. Jane-Valbuena, E. Todres, H. Specht, J. Golji, E. Kuhn, , S. A. Carr

The paper introduces SigPath, a mass spectrometry assay that quantifies 284 phosphosites across 200 phosphoproteins, revealing new insights into phospho-signaling in cancer models and human tumors.

bioRxiv · Dec 8, 2020Cancer Biology

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

S. A. Wander, O. Cohen, X. Gong, G. N. Johnson, J. Buendia-Buendia, M. R. Lloyd, D. Kim, F. Luo, P. Mao, K. Helvie, K. J. Kowalski, U. Nayar, A. G. Waks, S. Parsons, R. Martinez, , N. Wagle

The paper identifies eight resistance mechanisms to CDK4/6 inhibitors in HR+ breast cancer, present in 80% of resistant tumors, with potential therapeutic strategies.

bioRxiv · Nov 28, 2019Cancer Biology